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Abstract Autonomic dysfunction is a frequent and relevant
complication of diabetes mellitus, as it is associated with in-
creased morbidity and mortality. In addition, it is today con-
sidered as predictive of the most severe diabetic complica-
tions, like nephropathy and retinopathy. The classical methods
of screening are the cardiovascular reflex tests and were orig-
inally interpreted as evidence of nerve damage. A more mod-
ern approach, based on the integrated control of cardiovascu-
lar and respiratory function, reveals that these abnormalities
are to a great extent functional, at least in the early stage of the
disease, thus suggesting new potential interventions.
Therefore, this review aims to go further investigating how
the imbalance of the autonomic nervous system is altered
and can be influenced in many chronic pathologies through
a global view of cardio-respiratory and metabolic interactions
and how the same mechanisms are applicable to diabetes.
Keywords Chemoreflex . Baroreflex . Heart rate
variability . Diabetic neuropathy . Hypoxia . Autonomic
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Introduction
Autonomic abnormalities have long been described in pa-
tients with diabetes. These include both clinical symptoms
related to many organs (e.g., gut, bladder, reproductive
system) and functions (e.g., sweating, posture) but also
subclinical abnormalities that could be revealed by four
or five laboratory tests, originally described by Ewing [1]
and recently reviewed [2••], and based on cardiovascular
reflexes: heart rate variation during deep breathing, heart
rate and blood pressure variation at the beginning of
reaching the upright posture, heart rate changes during
the Valsalva maneuver, and the blood pressure response
to handgrip. Since the clinical symptoms are relatively
infrequent and the laboratory abnormalities are not clini-
cally appreciable by the patient, the relevance of the au-
tonomic dysfunction is often dismissed.
Nevertheless, subclinical autonomic dysfunction in diabe-
tes mellitus is probably one of the most relevant complica-
tions, as it is associated with increased morbidity and mortal-
ity [3], and in addition it is today considered as predictive of
the most severe diabetic complications, like nephropathy and
retinopathy [4–6].
In diabetic research, the abnormalities in the cardiovascular
reflex test are considered an evidence of “neuropathy” (e.g.,
nerve damage). This concept in fact derives from the first
observations of highly compromised, almost denervated pa-
tients [7, 8]. However, nowadays those extreme observations
are much less frequent, due to the tremendous improvement in
diabetic care, while still the frequency of subclinical autonom-
ic abnormalities remains very high, even before full-blown
diabetes develops [9]. These evidences make inconsistent
the attribution to “neuropathy,” at least in the initial or uncom-
plicated stage of diabetes, and point to a different interpreta-
tion of autonomic abnormalities.
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Indeed, the same alterations in the cardiovascular autonom-
ic tests can easily result from an imbalance of the autonomic
nervous system, with parasympathetic withdrawal and sym-
pathetic overactivation, rather than a nerve loss. This concept
is largely supported by observations in other clinical condi-
tions, like heart failure, hypertension, and chronic respiratory
diseases, where the same observations are considered as evi-
dence of autonomic “dysfunction” or “imbalance.” There are
two major theoretical and practical consequences of this dif-
ferent interpretation: (1) if indeed the neuropathy is preceded
by a periodmore or less prolonged of dysfunction, this implies
the potential of reversibility of this condition in diabetes and,
in view of the established prognostic and predictive relevance
of autonomic dysfunction, this also paves the way to new
potential preventive strategies for the diabetic complications,
and (2) a better understanding of the mechanisms underlying
the cardiovascular autonomic tests and their abnormalities be-
comes essential.
A comprehensive evaluation of the autonomic function
should therefore consider not just changes in heart rate in
response to some stimulus, but both the mechanisms that de-
termine such changes. These are multifarious, but mainly in-
volve the interplay of the control of blood pressure (mainly via
the baroreflexes) together with the control of respiration (via
the chemoreflexes) and their interaction.
Chemoreflexes and baroreflexes are tightly related (Fig. 1):
the chemoreflex induces a ventilatory response that, via the
sympathetic activation, is one of the most powerful modula-
tors of the arterial baroreflex, through direct interactions at the
integration centers and through respiratory-induced changes
in venous return, stroke volume, and blood pressure, which
modulate heart rate through the baroreflex [10, 11]. Baroreflex
alterations in turn modulate ventilation [12••]. Only with a
global view on the autonomic abnormalities can we under-
stand their real nature, hence we treat them appropriately.
Blood Pressure Regulation: the Baroreflex
The arterial baroreceptors, located mainly in the carotid
bodies and in the aortic arch, respond to acute increases
(or decreases) in blood pressure with both an increase (or
decrease) in parasympathetic (vagal) firing rate to the
heart, leading to a reduction (or increase) in heart rate
and thus a transient reduction (or increase) in cardiac out-
put and blood pressure, and also to a reduction (or in-
crease) in the sympathetic firing rate to the vessels, lead-
ing to a decrease (or increase) in peripheral resistances.
This reflex has the effect of stabilizing the blood pressure.
The arterial baroreflex, though only one of the many fac-
tors determining the blood pressure and its variations, is
considered the most important factor regulating the blood
pressure in the short term.
Baroreflex Sensitivity—Methodology
The parasympathetic cardiac arm of the baroreflex can be
easily measured, either by evaluating the heart rate change
to pharmachological interventions transiently increasing
or decreasing the blood pressure as originally proposed
[13], or more recently, by examining the heart rate re-
sponses to spontaneous fluctuations in blood pressure
(for example, periods of spontaneous increases or de-
creases in blood pressure, or else fluctuations at 0.1 Hz
or at the frequency of respiration). The spontaneous
methods showed to be a robust measure of baroreflex
sensitivity (BRS) with the advantage of not requiring in-
terventions [14–16].
A detailed description of the methods for obtaining the
baroreflex sensitivity is reported in previous publications
[16, 17•, 18••]. In practice, many methods are available,
even based on complex mathematical algorithms, but of-
ten these methods do not agree with each other. To over-
come these problems, our group recently proposed a new
technique, based on a simple mathematical algorithm (the
ratio of standard deviation of RR intervals/standard devi-
ation of systolic blood pressure) which showed the best
agreement with all other established methods [17•, 19].
Alternatively, the average or the median of all main avail-
able methods is a cumbersome but more robust option
than using a single standard method [17•, 19, 20].
Fig. 1 Simplified diagram of the
interactions between the control
of blood pressure and the control
of breathing
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Clinical and Prognostic Significance of Baroreflex
Abnormalities
The analysis of the spontaneous baroreflex can provide a more
sensitive diagnosis of autonomic dysfunction than cardiovas-
cular reflex tests as repeatedly shown in several studies [21,
22••], thereby allowing abnormalities of autonomic cardiac
modulation to be identified at an early stage and quantified
in a graded fashion [21, 22••]. It also showed a predictive
value for hypertension in a 5-year follow-up [23].
In cardiology, the baroreflex sensitivity is a well-
established predictor of cardiovascular mortality. The multi-
center Autonomic Tone and Reflexes After Myocardial
Infarction (ATRAMI) study provides clinical evidence that
after myocardial infarction the analysis of BRS has significant
prognostic value independently of left ventricular ejection
fraction and of ventricular arrhythmias [24••]. The
Card iovascu l a r Au tonomic Neu ropa thy (CAN)
Subcommittee of the Toronto Diabetic Neuropathy Expert
Group consider heart rate variability and BRS (especially the
cardiac-vagal arm) as important tests to evaluate the autonom-
ic function [18••]. The BRS assessment is an important com-
ponent of autonomic testing as it combines information de-
rived from both heart rate and blood pressure; moreover, it has
an independent prognostic value in cardiac and diabetic pa-
tients as it is a predictor of sudden death and all-cause mortal-
ity [25•, 26•].
Regulation of Breathing: the Chemoreflex
There are at least two types of receptors directly connected to
the regulation of breathing: the “central chemoreceptors,” lo-
cated in brain tissue of the medulla, more sensible to local
hydrogen ions and to carbon dioxide, and the “peripheral”
chemoreceptors, located in the carotid bodies, mainly sensible
to hypoxia and hydrogen ions [27]. Other receptors located in
the muscles play also an important role in heart failure [28••],
but still need to be studied in diabetes.
The chemoreceptors increase the frequency and depth of
breathing in response to a drop in the oxygen arterial partial
pressure or to an increase in the arterial partial pressure of
carbon dioxide, potassium, or hydrogen ions.
Chemoreflex Sensitivity—Methodology
The central and the peripheral chemoreflex responses may
be individually evaluated by specific techniques. The
mos t used today is the “ r eb rea th ing method.”
Rebreathing into a closed circuit causes a progressive re-
duction in the inspired oxygen and an increase in the
carbon dioxide concentration, both of which stimulate
ventilation. To assess the response to varying oxygen con-
centrations (hypoxic chemoreflex), the end-tidal carbon
dioxide pressure (CO2-et) is kept constant at baseline
values by absorbing its excess with soda lime. To test
the response to changes in carbon dioxide concentration
(hypercapnic chemoreflex), oxygen is continuously sup-
plied at a very low flow to maintain the percentage of
arterial oxygen saturation (SaO2) at baseline values
(>97 %). The tests end when SaO2 or CO2-et reach a
target value (80 % and 10–15 mmHg above baseline, re-
spectively). The chemoreflex sensitivity to hypoxia (hyp-
oxic ventilatory response) or hypercapnia (hypercapnic
ventilatory response) is obtained from the slope of the
linear regression linking minute ventilation vs SaO2 or
CO2et, respectively [11]. Alternatively, the gas concentra-
tion can be varied in several steps by inspiring different
gas mixtures (hypoxic or hypercapnic) during either sin-
gle breaths or fixed periods of time (e.g., 5-min, steady-
state method). Despite the theoretical precision of the
steady-state method, the fairly long time needed to reach
a steady-state ventilation in response to a given concen-
tration of inhaled gas caused severe problems in patients
with chemoreflex abnormalities [29, 30]. Conversely, the
rebreathing method resulted to be entirely safe [31]. Other
simpler methods measure the minute ventilation in re-
sponse to the carbon dioxide production (VE/VCO2 ratio),
which may prove useful particularly during exercise
[32••], and the even simpler ratio of tidal volume/
inspiratory time [33]. These simpler methods estimate a
“global chemosensitivity” and can be applied to continu-
ous monitoring, but do not provide specific information
on the central or peripheral chemoreceptors.
Clinical and Prognostic Significance of Chemoreflex
Abnormalities
Chemoreflex abnormalities play an important role in the path-
ogenesis and progression of heart failure. An augmented pe-
ripheral chemoreflex in chronic heart failure patients is asso-
ciated with hyperpnoea and tachycardia which increase the
severity of this pathology in terms of symptoms and exercise
limitation [34]. In turn, the tonic activation of excitatory
chemoreflex afferents contributes to increased efferent sym-
pathetic activity that worsens cardiovascular prognosis [35].
Thus, this process initiates a vicious circle in which the sym-
pathetic activity increases and the clinical condition worsens.
An increased chemoreflex highlights patients with more se-
vere heart failure and is an independent negative prognostic
marker [36•]. Recent studies show that ablation of the carotid
body chemoreceptors improves autonomic function and
breathing control in heart failure and improves survival [37,
38]. Additionally, the autonomic dysfunction assessed by al-
tered chemoreflex sensitivity predicts mortality in patients
with multiple organ dysfunction syndrome [39].
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Baroreflex-Chemoreflex Interaction
Evidence from animal models and human studies showed that
there is an antagonistic interaction between the chemoreflex
and the baroreflex, comprehensively reviewed in [12••] and
outlined in Fig. 1. For instance, in man [40], baroreflex acti-
vation selectively abolished the sympathetic nerve activity
response to hypoxia (move above citation here). This specific
interaction between the baroreceptors and the peripheral che-
moreceptors was explained by the convergence of barorecep-
tor and peripheral chemoreceptor afferents on neurons in the
medulla. Thus, baroreceptors exert a restraining influence
on the excitatory effect of chemoreceptors during hypox-
ia. In another study that included 13 healthy volunteers,
stimulation of chemoreceptors by hypercapnia or hypoxia
reduced heart rate variability and baroreflex sensitivity.
Conversely, stimulation of chemoreceptors by hypercap-
nia or hypoxia reduces heart rate variability and barore-
flex sensitivity [11]. Combined hypoxia and hypercapnia
have a synergistic effect on sympathetic activity as well as
on minute ventilation [41].
Baro-chemoreflex Interaction and Sympathovagal Imbalance
in Chronic Pathologies
Several studies showed that many relevant cardiovascular/
respiratory diseases (such as heart failure, hypertension, ob-
structive sleep apnea syndrome, and chronic obstructive pul-
monary diseases) exhibit potential vicious circles of reflex
derangements: the loss of cardiovascular control (baroreflex
attenuation) interplays with increased breathing stimulation
(chemoreflex augmentation) through a sustained sympathetic
activation and a reduced vagal activity [28••, 42••].
Congestive Heart Failure
Chronic congestive heart failure (CHF) is characterized by a
loss of pump function of the heart. The reduced cardiac output
and the resulting tissue hypoxia stimulate the sympathetic
activity leading to vasoconstriction, with increased afterload,
and hyperventilation. The increased afterload intensifies the
heart work, while the increased ventilation lowers the thresh-
old for the onset of dyspnea and thus reduces the exercise
performance [36•]. Peripheral vasoconstriction aggravates tis-
sue hypoxia, which, together with the sympathetic activation,
leads to chronic low-grade inflammation, insulin resistance
(both often promoting diabetes development), endothelial
dysfunction, and oxidative stress.
The impaired cardiac autonomic activity in CHF
(expressed as reduced heart rate variability or depressed arte-
rial baroreflex sensitivity) is associated with an increased pe-
ripheral chemosensitivity, suggesting a link between the
chemoreflex and the baroreflex in a clear inverse relationship
[43•], contributing further to sympathetic overactivity, blunted
baroreflex function, and ultimately poor prognosis in CHF
patients [44].
Thus, these autonomic, metabolic, and cardiovascular ab-
normalities are linked in a progressive vicious circle (Fig. 2).
For instance, a study conducted in 14 men with CHF demon-
strated a significant positive correlation between sympathetic
nerve activity and breathing frequency and an inverse corre-
lation between sympathetic activity and tidal volume [45••].
Hence, the patients with rapid shallow breathing seem to ex-
hibit the highest degree of sympathetic activation and the
worse prognosis [45••]. Slow-deep breathing training im-
proves oxygenation, heart rate variability, and exercise perfor-
mance in heart failure [46]. The abnormalities described above
are thus implicated in the reduced exercise performance of the
patients with heart failure, and interventions aimed at restoring
the cardio-respiratory control (e.g., physical exercise) im-
proved both cardiovascular regulation and exercise tolerance,
hence resulting in important clinical improvement in these
patients [47].
Obstructive Sleep Apnea Syndrome
Obstructive sleep apnea syndrome (OSAS) is frequent in type
2 diabetic patients. Diabetes and OSAS exert a bidirectional
influence, with diabetes predisposing to or aggravating
OSAS, and OSAS predisposing to or aggravating diabetes
[48••]. Furthermore, there is a large amount of evidence
linking OSAS, the intermittent hypoxia, and the carbon diox-
ide retention that accompany it, with the development of hy-
pertension [49•, 50]. The chemoreflex responds acutely to
intermittent hypoxic exposure with an increase in sympathetic
activity; the subsequent rise in blood pressure initiates a com-
pensatory baroreflex response that attempts to buffer these
changes. This mechanism was originally described only for
the central apneas, but it is now clear that the autonomic ner-
vous system is highly involved also in the obstructive apneas
[51]. With chronic exposure to intermittent hypoxia, a sensi-
tization of peripheral chemoreflex occurs. Conversely, barore-
flex may become desensitized: the exposure to intermittent
hypoxia resets the baroreflex to operate at higher levels of
sympathetic activity and blood pressure [52]. During the early
phase of apnea, the muscle sympathetic nerve activity
(MSNA) is suppressed; it then increases constantly and
reaches a peak at the end of apnea and on arousal. The re-
sumption of ventilation occurs in the context of peripheral
vasoconstriction and increased peripheral resistance. This sit-
uation persists for several seconds after theMSNA has ceased,
due to the kinetics of norepinephrine uptake, release, and
washout at the neurovascular junction. The alterations in the
autonomic nervous system are carried over into wakefulness
and may contribute to the development of the cardiovascular
disorders associated with OSAS, including sympathovagal
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imbalance. Several neural and humoral mechanisms may con-
tribute to maintenance of higher sympathetic activity and
blood pressure even during daytime wakefulness when sub-
jects are breathing normally, and no evidence of hypoxia or
chemoreflex activation is apparent. These mechanisms in-
clude chemoreflex and baroreflex dysfunction, altered cardio-
vascular variability, vasoconstrictor effects of nocturnal
endothelin release, and endothelial dysfunction [53].
Notably, it has been reported that hemodynamic and autonom-
ic dysfunction associated with OSAS may improve with con-
tinuous positive airway pressure (CPAP) [54, 55]). One month
of treatment of nasal CPAP readjusted the peripheral oxygen
chemosensitivity (normocapnic hypoxic ventilatory response
reduced in patients but not in controls). This change may be a
side effect of both reduced sympathetic activity and increased
baroreflex activity, or a possible CPAP-related mechanism
leading to a reduced activation of autonomic nervous system
per se [56].
Obstructive and Restrictive Lung Diseases
Conditions like chronic obstructive pulmonary disease (COPD)
and restrictive lung diseases that induce respiratory failure and
chronic hypoxemia may lead to autonomic imbalance with an
increased sympathetic activity. MSNA was higher in patients
with chronic respiratory failure compared with healthy matched
subjects. Additionally, the sympathetic activity decreased during
oxygen administration in the patients but not in the controls. The
higher sympathetic tone could be explained by the arterial
chemoreflex activation present in these patients and may play
an important role in the pathogenesis of the disease [57].
COPD causes neurohumoral activation, and its negative conse-
quences, namely, inflammation, cachexia, skeletal muscle dys-
function, and insulin-resistance, give rise to a self-perpetuating
cycle that contributes to the pathogenesis of COPD [58], similar
to CHF (Fig. 2). In COPD, MSNA showed evidence of sympa-
thetic overactivation and decreased baroreflex sensitivity even in
normoxic patients. These findings suggest the sympathovagal
imbalance as a pathophysiological phenomenon in COPD
[59•]. A study testing the effect of hypoxic training in patients
with mild COPD demonstrated the presence of cardiovascular
autonomic abnormalities (depressed baroreflex sensitivity) even
if there were no chemoreflex abnormalities. After training, baro-
reflex sensitivity increased up to normal levels and hypercapnic
ventilatory response increased as well without changes in hyp-
oxic ventilatory response [60]. The administration of oxygen or
the slowing of breathing rate resulted in significant improvement
of BRS and a decrease in mean heart rate and arterial pulse
pressure in patients with COPD [59•, 61].
Cardio-Respiratory Control in Diabetes
Although some studies have investigated the hypothesis of an
altered cardiovascular or respiratory control in diabetes, the
chemoreflexes and baroreflexes were tested only in a small
number of patients and only separately. Thus, in diabetes, the
cardio-respiratory-integrated control remains to a large extent
to be investigated.
Fig. 2 Diagram of the abnormal
interactions between the control
of blood pressure and the control
of breathing in diabetes
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It is known that the impairment of autonomic function could
be observed at an early stage of diabetes by a depressed BRS [14,
21]. Nevertheless, diabetic patients are able to increase BRS in
response to slow deep breathing, an intervention capable of re-
ducing the sympathetic and enhancing the parasympathetic ac-
tivity. In contrast, really denervated patients (as for instance after
heart transplantation) could not increase BRS. These findings
indicate that the autonomic nervous system of type 1 diabetic
patients may still be able to react to a simple intervention and
thus that the abnormalities in type 1 diabetes are to some extent
functional at least at an early stage of the disease [22••]. Another
study showed that both oxygen and slow breathing increased
BRS in a group of 96 type 1 diabetic participants, in which
BRS was depressed at baseline, equally or more than in healthy
control participants. The larger-than-normal response to
hyperoxia suggests a pre-existing condition of tissue hypoxia that
functionally restrains parasympathetic activity in these patients.
These studies indicate that autonomic abnormalities can be par-
tially and temporarily reversed by simple maneuvers such as
slow breathing or oxygen administration through enhancement
of parasympathetic activity and/or correction of tissue hypoxia
[62••]. Similar results (improvement in BRS) were found also in
type 2 diabetic patients with chronic kidney disease after two
different procedures that increase blood oxygenation (slow deep
breathing and oxygen administration), suggesting a functional
role of hypoxia even in complicated diabetic patients [63•]. All
these findings suggest a potential link between baroreflex abnor-
malities and impaired control of respiration (chemoreflexes).
There are only a few studies evaluating the chemoreflexes
in diabetes, indicating in general a reduced response to oxygen
and a normal or exaggerated response to carbon dioxide.
However, these studies were carried out in small groups of
subjects, evaluating either the central [64••], the peripheral
[65•] chemoreflex, or both [66•], but none included a measure
of BRS. .
In a preliminary study carried out in 46 type-1 diabetic and
103 control subjects, we showed that in diabetic patients the
reduced BRS is accompanied by an enhancement in the hy-
percapnic chemoreflex, whereas the responses to hypoxia
showed a trend toward a reduction, despite that the resting
oxygen saturation was significantly depressed [67].
These findings suggest a possible role of hypoxia (in associ-
ation to hyperglycemia) in inducing BRS and chemoreflex dys-
function, as well as downstream diabetic complications [68•, 69].
Hyperglycemia and other cellular abnormalities (low-grade
inflammation, oxidative stress) seem to blunt the function of
hypoxia-inducible factor-1 (HIF-1), a transcription factor that is
essential for adaptive responses of the cells to hypoxia [70•,
71••]. At the same time, the hypercapnia-induced sympathetic
activation might in turn depress baroreflex, heart rate variability,
and autonomic function tests [41]. A schematic representation of
these mechanisms is shown in Fig. 2.
Conclusion
What We Learned and What Is the Practical Significance
of the Abnormal Integration of Cardiovascular
and Respiratory Reflexes in Diabetes?
This review underlines the basic concept that the regulations of
ventilation and blood pressure are tightly interconnected, that this
interplay is altered in diabetes, and that hypoxia, either/both as a
cause or as a consequence, is present in diabetes [62••]. Starting
from this new approach, we showed that early autonomic dys-
function is reversible [22••] and that rebalancing of the autonom-
ic reflexes and correction of hypoxia are theoretically possible.
Because respiration is not only automatic but also under volition-
al control, a specific respiratory pattern may interfere with both
the cardiovascular and the respiratory systems, thus potentially
helping the restoration of a more physiological balance. We and
others showed that slow deep breathing transiently improves
oxygen saturation, enhances baroreflex sensitivity, and reduces
the chemoreflex response to both hypoxia and hypercapnia [11]
Table 1 Comparative schematic
effects of slow breathing and
physical training, with respect to
the baroreflex-chemoreflex
interaction, as demonstrated in
different pathologies (CHF,
COPD, hypertension, diabetes)
Effect Slow breathing Physical training
Short-term Long-term Short-term Long-term
Sympathetic suppression + ? − +
Parasympathetic enhancement + ? − +
Increase in BRS + ? − +
Increase in heart rate variability + ? − +
Reduced chemoreflex hyperactivity + + − +
Arterial/tissue oxygenation + ? + +
Improved exercise capacity + +
Anti-inflammatory effect ? ? − +
Antioxidant effect + ? − +
+ positive effect, − negative effect, ? unknown
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in healthy subjects; in patients with CHF [72], COPD [59•], or
hypertension [73]; and in diabetes patients [22••], in addition to
suppressing the sympathetic nerve activity in conditions of sym-
pathetic activation such as CHF [45••, 74] and COPD [59•]:
more recent results indicate that the vagal stimulation exerted
by slow breathing reduces the free radical excess in diabetic
patients [75], similar to what occurs with vagal nerve stimulators
in heart failure [76–78]. This apparently simple intervention has
in fact amultidimensional effect and reveals potentials in diabetic
autonomic dysfunction, as it seems to correct several basic prob-
lems, at least in the short-term application. In the long term,
promising results seem to occur in diabetes by effect of yoga, a
technique in which various forms of slow breathing are largely
employed [79, 80]. In addition, the same results (improvement in
tissue oxygenation, reduction of chemoreflex activation, im-
provement in parasympathetic activity and BRS, increase in an-
tioxidant reserve, and reduced free radical excess) that can be
obtained with slow breathing also occur with physical exercise
(Table 1). This review then suggests a rather new reason for
encouraging physical exercise in diabetes, in addition to other
potential treatments, like hypoxic training [20, 81] or drugs
which stabilize and activate HIF [82]. All these interventions,
based on the knowledge of the cardio-respiratory reflex interac-
tion, have the potential to be helpful in improving the autonomic
dysfunction and the sensitivity to hypoxia and finally prevent
diabetic complications.
Compliance with Ethical Standards
Conflict of Interest Luciano Bernardi and Lucio Bianchi declare that
they have no conflict of interest.
Human and Animal Rights and Informed Consent This article does
not contain any studies with human or animal subjects performed by any
of the authors.
References
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
•• Of major importance
1. Ewing DJ, Campbell IW, Clarke BF. Assessment of cardiovascular
effects in diabetic autonomic neuropathy and prognostic implica-
tions. Ann Intern Med. 1980;92(2 Pt 2):308–11.
2.•• Spallone V, Ziegler D, Freeman R, et al. Cardiovascular autonomic
neuropathy in diabetes: clinical impact, assessment, diagnosis, and
management. Diabetes Metab Res Rev. 2011;27(7):639–53.
doi:10.1002/dmrr.1239. Review on clinical autonomic tests in
diabetes.
3. Maser RE, Mitchell BD, Vinik AI, et al. The association between
cardiovascular autonomic neuropathy and mortality in individuals
with diabetes: a meta-analysis. Diabetes Care. 2003;26(6):1895–
901.
4. Duvnjak L, TomićM, Blaslov K, et al. Autonomic nervous system
function assessed by conventional and spectral analysis might be
useful in terms of predicting retinal deterioration in persons with
type 1 diabetes mellitus. Diabetes Res Clin Pract. 2016;116:111–6.
doi:10.1016/j.diabres.2016.04.042.
5. Wheelock KM, Jaiswal M, Martin CL, et al. Cardiovascular auto-
nomic neuropathy associates with nephropathy lesions in American
Indians with type 2 diabetes. J Diabetes Complicat. 2016;30(5):
873–9. doi:10.1016/j.jdiacomp.2016.03.008.
6. Salman IM. Cardiovascular autonomic dysfunction in chronic kid-
ney disease: a comprehensive review. Curr Hypertens Rep.
2015;17(8):59. doi:10.1007/s11906-015-0571-z.
7. Wheeler T, Watkins PJ. Cardiac denervation in diabetes. Br Med J.
1973;4(5892):584–6.
8. Duchen LW, Anjorin A, Watkins PJ, et al. Pathology of autonomic
neuropathy in diabetes mellitus. Ann Intern Med. 1980;92(2 Pt 2):
301–3.
9. Ziegler D, Voss A, Rathmann W, KORA Study Group, et al.
Increased prevalence of cardiac autonomic dysfunction at different
degrees of glucose intolerance in the general population: the KORA
S4 survey. Diabetologia. 2015;58(5):1118–28. doi:10.1007
/s00125-015-3534-7.
10. Sleight P, La Rovere MT, Mortara A, et al. Physiology and patho-
physiology of heart rate and blood pressure variability in humans: is
power spectral analysis largely an index of baroreflex gain? Clin
Sci. 1995;88:103–9.
11. Bernardi L, Gabutti A, Porta C, et al. Slow breathing reduces
chemoreflex response to hypoxia and hypercapnia, and increases
baroreflex sensitivity. J Hypertens. 2001;19(12):2221–9.
12.•• Francis DA, Coats JS, Ponikowski P. Chemoreflex-baroreflex inter-
actions in cardiovascular disease. In: Bradley TD, Floras JS, editors.
Sleep apnea. Implication in cardiovascular and cerebrovascular dis-
ease. New York: Marcel Dekker; 2000. p. 261–83. Describes the
reciprocal interaction between control of breathing and control
of circulation.
13. Bristow JD, Honour AJ, Pickering GW, et al. Diminished barore-
flex sensitivity in high blood pressure. Circulation. 1969;39(1):48–
54.
14. Frattola A, Parati G, Gamba P, et al. Time and frequency domain
estimates of spontaneous baroreflex sensitivity provide early detec-
tion of autonomic dysfunction in diabetes mellitus. Diabetologia.
1997;40(12):1470–5.
15. Sykora M, Diedler J, Rupp A, et al. Impaired baroreflex sensitivity
predicts outcome of acute intracerebral hemorrhage. Crit CareMed.
2008;36:3074–9.
16. Laude D, Elghozi JL, Girard A, et al. Comparison of various tech-
niques used to estimate spontaneous baroreflex sensiivity (the
EuroBaVar study). Am J Physiol Regul Integr Comp Physiol.
2004;286:R226–31.
17.• Bernardi L, De Barbieri G, Rosengård-BärlundM, et al. Newmeth-
od to measure and improve consistency of baroreflex sensitivity
values. Clin Auton Res. 2010;20(6):353–61. Describes a new
method to measure baroreflex sensitivity and compare it with
all other methods, showing that the new method has higher
robustness and in agreement with the rest of methods.
18.•• Bernardi L, Spallone V, Stevens M, et al. Methods of investigation
for cardiac autonomic dysfunction in human research studies.
Toronto Consensus Panel on Diabetic Neuropathy. Diabetes
Metab Res Rev. 2011;27(7):654–64.Review describing in critical
terms the most relevant methods for research, with special em-
phasis to the misconceptions related to heart rate variability-
based methods.
19. Mirizzi G, Giannoni A, Bramanti F, et al. A simple method for
measuring baroreflex sensitivity holds prognostic value in heart
Curr Diab Rep (2016) 16: 107 Page 7 of 9 107
failure. Int J Cardiol. 2013;169(1):e9–11. doi:10.1016/j.
ijcard.2013.08.120.
20. Duennwald T, Bernardi L, Gordin D, FinnDiane Study Group, et al.
Effects of a single bout of interval hypoxia on cardiorespiratory
control in patients with type 1 diabetes. Diabetes. 2013;62(12):
4220–7. doi:10.2337/db13-0167.
21. Ducher M, Cerutti C, Gustin MP, et al. Noninvasive exploration of
cardiac autonomic neuropathy. Four reliable methods for diabetes?
Diabetes Care. 1999;22(3):388–93.
22.•• Rosengård-Bärlund M, Bernardi L, Fagerudd J, FinnDiane Study
Group, et al. Early autonomic dysfunction in type 1 diabetes: a
reversible disorder? Diabetologia. 2009;52(6):1164–72.
doi:10.1007/s00125-009-1340-9. Describes for the first time
that autonomic dysfunction is potentially reversible.
23. Rosengård-Bärlund M, Bernardi L, Sandelin A, et al. Baroreflex
sensitivity and its response to deep breathing predict increase in
blood pressure in type 1 diabetes in a 5-year follow-up. Diabetes
Care. 2011;34(11):2424–30. doi:10.2337/dc11-0629.
24.•• La Rovere MT, Bigger Jr JT, Marcus FI, et al. Baroreflex sensitivity
and heart-rate variability in prediction of total cardiacmortality after
myocardial infarction. ATRAMI (Autonomic Tone and Reflexes
After Myocardia l Infarc t ion) Inves t iga tors . Lancet .
1998;351(9101):478–84. One of the most important papers
showing the prognostic power of baroreflex sensitivity in cardi-
ac patients.
25.• Johansson M, Gao SA, Friberg P, et al. Baroreflex effectiveness
index and baroreflex sensitivity predict all-cause mortality and sud-
den death in hypertensive patients with chronic renal failure. J
Hypertens. 2007;25(1):163–8.Another important paper showing
the prognostic power of baroreflex sensitivity in hypertensive
patients.
26.• Gerritsen J, Dekker JM, TenVoorde BJ, et al. Impaired autonomic
function is associated with increased mortality, especially in sub-
jects with diabetes, hypertension, or a history of cardiovascular
disease: the Hoorn Study. Diabetes Care. 2001;24(10):1793–8.
This paper reports some information about the prognostic val-
ue of baroreflex sensitivity in diabetes.
27. Duffin J. The chemoreflex control of breathing and measurement.
Can J Anaesth. 1990;37(S):933–42.
28.•• Piepoli MF, Coats AJ. The ‘skeletal muscle hypothesis in heart failure’
revised. Eur Heart J. 2013;34(7):486–8. doi:10.1093/eurheartj/ehs463.
Describes the “muscle hypothesis” in heart failure. In the paper, we
describe how this seems to apply to diabetes as well.
29. EdelmanNH, CherniackNS, Lahiri S, et al. The effects of abnormal
sympathetic nervous function upon the ventilatory response to hyp-
oxia. J Clin Invest. 1970;49(6):1153–65.
30. Duffin J. Measuring the ventilatory response to hypoxia. J Physiol.
2007;584(Pt1):285–93.
31. Bernardi L, Hilz M, Stemper B, et al. Respiratory and cerebrovas-
cular responses to hypoxia and hypercapnia in familial
dysautonomia. Am J Respir Crit Care Med. 2003;167(2):141–9.
32.•• Ponikowski P, Francis DP, Piepoli MF, et al. Enhanced ventilatory
response to exercise in patients with chronic heart failure and pre-
served exercise tolerance: marker of abnormal cardiorespiratory
reflex control and predictor of poor prognosis. Circulation.
2001;103(7):967–72. Describes the prognostic significance of
chemoreflex abnormalities.
33. Van den Aardweg JG, Karemaker JM. Influence of chemoreflexes
on respiratory variability in healthy subjects. Am J Respir Crit Care
Med. 2002;165(8):1041–7.
34. Chua TP, Ponikowski P, Coats AJ, et al. Clinical characteristics of
chronic heart failure patients with an augmented peripheral
chemoreflex. Eur Heart J. 1997;18(3):480–6.
35. Despas F, Detis N, PathakA, et al. Excessive sympathetic activation
in heart failure with chronic renal failure: role of chemoreflex
activation. J Hypertens. 2009;27(9):1849–54. doi:10.1097/HJH.0
b013e32832e8d0f.
36.• Chua TP, Ponikowski P, Harrington D, et al. Clinical correlates and
prognostic significance of the ventilatory response to exercise in
chronic heart failure. J Am Coll Cardiol. 1997;29(7):1585–90.
Describes the prognostic significance of chemoreflex
abnormalities.
37. Andrade DC, Lucero C, Toledo C, et al. Relevance of the carotid
body chemoreflex in the progression of heart failure. Biomed Res
Int. 2015;2015:467597. doi:10.1155/2015/467597.
38. Del Rio R,MarcusNJ, Schultz HD. Carotid chemoreceptor ablation
improves survival in heart failure: rescuing autonomic control of
cardiorespiratory function. J Am Coll Cardiol. 2013;62(25):2422–
30. doi:10.1016/j.jacc.2013.07.079.
39. Schmidt H, Müller-Werdan U, Hoffmann T, et al. Autonomic dys-
function predicts mortality in patients with multiple organ dysfunc-
tion syndrome of different age groups. Crit Care Med. 2005;33(9):
1994–2002.
40. Mancia G. Influence of carotid baroreceptors on vascular responses
to carotid chemoreceptor stimulation in the dog. Circ Res. 1975;36:
270–6.
41. Somers VK, Mark AL, Zavala DC, et al. Contrasting effects of
hypoxia and hypercapnia on ventilation and sympathetic activity
in humans. J Appl Physiol (1985). 1989;67(5):2101–6.
42.•• Coats AJ, Clark AL, Piepoli M, et al. Symptoms and quality of life
in heart failure: the muscle hypothesis. Br Heart J. 1994;72(2
Suppl):S36–9. Another key reference to the “muscle hypothe-
sis”. In the paper we show its relevance in diabetes.
43.• Ponikowski P, Chua TP, Piepoli M, et al. Augmented peripheral
chemosensitivity as a potential input to baroreflex impairment and
autonomic imbalance in chronic heart failure. Circulation.
1997;96(8):2586–94. Describes the reciprocal interaction be-
tween chemoreflexes and baroreflexes in heart failure.
44. Despas F, Lambert E, Vaccaro A, et al. Peripheral chemoreflex
activation contributes to sympathetic baroreflex impairment in
chronic heart failure. J Hypertens. 2012;30(4):753–60.
45.•• NaughtonMT, Floras JS, Rahman MA, et al. Respiratory correlates
of muscle sympathetic nerve activity in heart failure. Clin Sci
(Lond). 1998;95(3):277–85. Describes the interaction between
breathing pattern and sympathetic activity.
46. Bernardi L, Spadacini G, Bellwon J, et al. Effect of breathing rate
on oxygen saturation and exercise performance in chronic heart
failure. Lancet. 1998;351(9112):1308–11.
47. Coats AJ, Adamopoulos S, Radaelli A, et al. Controlled trial of
physical training in chronic heart failure. Exercise performance,
hemodynamics, ventilation, and autonomic function. Circulation.
1992;85(6):2119–31.
48.•• Greco C, Spallone V. Obstructive sleep apnoea syndrome and dia-
betes. Fortuitous association or interaction? Curr Diabetes Rev.
2015;12(2):129–55. A key review on sleep apnea syndrome.
49.• Narkiewicz K, Somers VK. The sympathetic nervous system and
obstructive sleep apnea: implications for hypertension. J Hypertens.
1997;15(12 Pt 2):1613–9.Describes the interaction between sym-
pathetic activity and sleep apnea.
50. Phillips BG, Somers VK. Neural and humoral mechanisms medi-
ating cardiovascular responses to obstructive sleep apnea. Respir
Physiol. 2000;119(2–3):181–7.
51. Spicuzza L, Bernardi L, Calciati A, et al. Autonomic modulation of
heart rate during obstructive versus central apneas in patients with
sleep-disordered breathing. Am J Respir Crit Care Med.
2003;167(6):902–10.
52. Freet CS, Stoner JF, Tang X. Baroreflex and chemoreflex controls
of sympathetic activity following intermittent hypoxia. Auton
Neurosci. 2013;174(1–2):8–14. doi:10.1016/j.autneu.2012.12.005.
53. Narkiewicz K, Somers VK. Sympathetic nerve activity in obstruc-
tive sleep apnoea. Acta Physiol Scand. 2003;177(3):385–90.
107 Page 8 of 9 Curr Diab Rep (2016) 16: 107
54. Lurie A. Adv Cardiol. 2011;46:171–95. doi:10.1159/000325109.
Hemodynamic and autonomic changes in adults with
obstructive sleep apnoea.
55. Bonsignore MR, Parati G, Insalaco G, et al. Continuous positive
airway pressure treatment improves baroreflex control of heart rate
during sleep in severe obstructive sleep apnoea syndrome. Am J
Respir Crit Care Med. 2002;166:279–86.
56. Spicuzza L, Bernardi L, Balsamo R, et al. Effect of treatment with
nasal continuous positive airway pressure on ventilatory response to
hypoxia and hypercapnia in patients with sleep apnea syndrome.
Chest. 2006;130(3):774–9.
57. Heindl S, Lehnert M, Criée CP, et al. Marked sympathetic activa-
tion in patients with chronic respiratory failure. Am J Respir Crit
Care Med. 2001;164:597–601.
58. Andreas S, Anker SD, Scanlon PD, et al. Neuro-humoral activation
as a link to systemic manifestations of chronic lung disease. Chest.
2005;128:3618–24.
59.• Raupach T, Bahr F, Herrmann P, et al. Slow breathing reduces
sympathoexcitation in COPD. Eur Respir J. 2008;32(2):387–92.
doi:10.1183/09031936.00109607. Shows the sympathetic
overactivation in COPD and its reduction with slow breathing.
60. Haider T, Casucci G, Linser T, et al. Interval hypoxic training im-
proves autonomic cardiovascular and respiratory control in patients
with mild chronic obstructive pulmonary disease. J Hypertens.
2009;27(8):1648–54.
61. Bartels MN, Gonzalez JM, Kim W, et al. Oxygen supplementation
and cardiac autonomic modulation in COPD. Chest. 2000;118(3):
691–6.
62.•• Bernardi L, Rosengård-Bärlund M, Sandelin A, FinnDiane Study
Group, et al. Short-term oxygen administration restores blunted
baroreflex sensitivity in patients with type 1 diabetes.
Diabetologia. 2011;54(8):2164–73. This paper shows that the
parasympathetic reduction results from functional impairment
in type 1 diabetes, since it was corrected by oxygen administra-
tion, and that hypoxia could be the cause for it.
63.• Esposito P,Mereu R, De Barbieri G et al. Trained breathing-induced
oxygenation acutely reverses cardiovascular autonomic dysfunction
in patients with type 2 diabetes and renal disease. Acta Diabetol.
2015. This paper shows similar results as the previous, in type 2
diabetes also with renal impairment.
64.•• Tantucci C, Scionti L, Bottini P, et al. Influence of autonomic neu-
ropathy of different severities on the hypercapnic drive to breathing
in diabetic patients. Chest. 1997;112(1):145–53. Describes
chemoreflex impairment in diabetes.
65.• Weisbrod CJ, Eastwood PR, O’Driscoll G, et al. Abnormal ventila-
tory responses to hypoxia in Type 2 diabetes. Diabet Med.
2005;22(5):563–8. Describes chemoreflex impairment in
diabetes.
66.• Nishimura M, Miyamoto K, Suzuki A, et al. Ventilatory and heart
rate responses to hypoxia and hypercapnia in patients with diabetes
mellitus. Thorax. 1989;44(4):251–7. Describes chemoreflex im-
pairment in diabetes.
67. Bianchi L, Porta C, A. Rinaldi et al. Integrated cardiovascular/
respiratory control in type 1 diabetes. Accepted abstract, EASD
2015 Stockholm
68.• Miyata T, de Strihou C. Diabetic nephropathy: a disorder of oxygen
metabolism? Nat Rev Nephrol. 2010;6:83–95.Describes how hyp-
oxia could be responsible to diabetic neuropathy.
69. Williamson JR, Chang K, Frangos M, et al. Hyperglycemic
pseudohypoxia and diabetic complications. Diabetes. 1993;42:
801–13.
70.• Catrina SB, Okamoto K, Pereira T, et al. Hyperglycemia regulates
hypoxia-inducible factor-1 alpha protein stability and function.
Diabetes. 2004;53(12):3226–32. Describes the molecular basis
of hypoxia in diabetes and its impact on hypoxia-inducible
factor.
71.•• Bento CF, Pereira P. Regulation of hypoxia-inducible factor 1 and
the loss of the cellular response to hypoxia in diabetes.
Diabetologia. 2011;54(8):1946–56.This review describes the role
of hypoxia-inducible factor in diabetes.
72. Bernardi L, Porta C, Spicuzza L, et al. Slow breathing increases
arterial baroreflex sensitivity in patients with chronic heart failure.
Circulation. 2002;105(2):143–5.
73. Joseph CN, Porta C, Casucci G, et al. Slow breathing improves
arterial baroreflex sensitivity and decreases blood pressure in essen-
tial hypertension. Hypertension. 2005;46(4):714–8.
74. GosoY, Asanoi H, Ishise H, et al. Respiratorymodulation of muscle
sympathetic nerve activity in patients with chronic heart failure.
Circulation. 2001;104(4):418–23.
75. Bianchi L, Bernardi L, Ghelardi R et al. Accepted abstract, EASD
Munich 2016
76. Vimercati C, Qanud K, Ilsar I, et al. Acute vagal stimulation atten-
uates cardiac metabolic response to β-adrenergic stress. J Physiol.
2012;590(23):6065–74. doi:10.1113/jphysiol.2012.241943.
77. Gupta RC, Imai M, Jiang AJ, et al. Chronic therapy with selective
electric vagus nerve stimulation normalizes plasma concentration of
tissue necrosis factor-α, interleukin- 6 and B- type natriuretic pep-
tide in dogs with heart failure. J Am Coll Cardiol. 2006;47:77A.
78. Kong SS, Liu JJ, Yu XJ, et al. Protection against ischemia-induced
oxidative stress conferred by vagal stimulation in the rat heart:
involvement of the AMPK-PKC pathway. Int J Mol Sci.
2012;13(11):14311–25. doi:10.3390/ijms131114311.
79. Hegde SV, Adhikari P, Kotian S, et al. Effect of 3-month yoga on
oxidative stress in type 2 diabetes with or without complications: a
controlled clinical trial. Diabetes Care. 2011;34(10):2208–10.
doi:10.2337/dc10-2430.
80. Gordon L, Morrison EY, McGrowder D, et al. Effect of yoga and
traditional physical exercise on hormones and percentage insulin
binding receptor in patients with type 2 diabetes. Am J Biochem
Biotechnol. 2008;4(1):35–42. doi:10.3844/ajbbsp.2008.35.42.
81. Duennwald T, Gatterer H, Groop PH, et al. Effects of a single bout
of interval hypoxia on cardiorespiratory control and blood glucose
in patients with type 2 diabetes. Diabetes Care. 2013;36(8):2183–9.
82. Xiao H, Gu Z, Wang G, et al. The possible mechanisms underlying
the impairment of HIF-1α pathway signaling in hyperglycemia and
the beneficial effects of certain therapies. Int J Med Sci.
2013;10(10):1412–21.
Curr Diab Rep (2016) 16: 107 Page 9 of 9 107
